22nd Mar 2016 09:33
For immediate release | 22 March 2016 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR Shareholding: LTIP
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that on 21 March 2016, the PDMR listed below was granted a share award in the form of Nil Cost Options under the Abcam plc Long-Term Incentive Plan ("LTIP"):
Name | Number of 0.2 pence Ordinary Shares subject to the LTIP Award
|
Suzanne Smith | 17,241 |
The Awards will vest in three years' time subject to continued employment and subject to the satisfaction of performance conditions based on earnings per share growth and meeting strategic KPIs.
For further information, please contact:
Abcam | + 44 (0) 1223 696 000 |
Suzanne Smith, Company Secretary
| |
J.P.Morgan Cazenove - Nominated Adviser & Corporate Broker | + 44 (0) 20 7742 4000 |
James Mitford / Alex Bruce - Nominated Adviser | |
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Abcam's ten offices are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and www.abcamplc.com
Related Shares:
ABC.L